$3bn
South Africa’s market regulator says it is reviewing volatile share trading sparked by market speculation that a research group would release a negative report on a listed firm. The regulator confirmed it was reviewing unusual activity in shares of Aspen Pharmacare, which plunged 10 percent o
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```